

The IMPACT Study – Identification of Men with a genetic predisposition to Prostate cancer: Targeted screening in *BRCA1/2* mutation carriers and controls

The IMPACT study is an international targeted prostate screening study of men at increased prostate cancer risk due to the presence of known pathogenic mutations in *BRCA1* and *BRCA2* genes.

Study Aims

- To establish an international targeted prostate cancer screening study in *BRCA1* & *BRCA2* carriers
- To determine the incidence of raised PSA and abnormal biopsy in this group
- To gain a better understanding of the pathogenesis of Prostate Cancer in men with *BRCA1/2* mutations.

Inclusion Criteria


- Men with a known *BRCA1* or *BRCA2* mutation
- Male who has tested negative for a known *BRCA1/2* mutation present within their family
- Age 40-69 years
- No previous history of prostate cancer
- No previous prostate biopsy for raised PSA

Exclusion Criteria

- Previous cancer with a terminal prognosis of less than five years.

What is Involved?

- Each subject's family history of cancer will be updated and a clinical history will be taken.
- Annual PSA test (at local and central centres) and storage of serum, plasma and urine samples for a total of 5 years, with 5 years follow-up.



Contact:

Liz Bancroft, Research Nurse
The Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, UK
Email: Elizabeth.Bancroft@rmh.nhs.uk
Tel: 0207 808 2136
Fax: 0208 770 1489